Canopy Growth Corp

Aktienanalyse zu Canopy Growth Corp (CGC)

$0.713

-0.022 (-3.06%)Zum Schluss

Loading chart…
Hoch
0.756
Eröffnung
0.752
Volumengewichteter Durchschnittskurs
0.72
Volumen
2.41M
Marktkap.
508.24M
Tief
0.702
Umsatz
1.74M
EV/EBITDA, TTM
-6.00

Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany.

KI-Analyse of Canopy Growth Corp (CGC)

Verkaufen

Canopy Growth Corp is not a good buy right now due to its current price of 0.713, a very low RSI of 17.94 indicating oversold conditions, and a troubling forward P/E of 20.37, which suggests high expectations despite ongoing losses.

Bewertungskennzahlen

Das aktuelle erwartete KGV von Canopy Growth Corp (CGC) beträgt 20.37, verglichen mit dem 5-Jahres-Durchschnitt von -1.24.

Erwartetes KGV

Stark überbewertet
5J-Durchschnitt P/E
-1.24
Aktuelles P/E
20.37
Überbewertet
8.72
Unterbewertet
-11.20

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
-274.73
Aktuelles EV/EBITDA
-6.00
Überbewertet
449.33
Unterbewertet
-998.79

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
2.93
Aktuelles P/S
0.87
Überbewertet
5.23
Unterbewertet
0.64

Alphio-AI-Kursszenarien für CGC

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%CGC

$1.78

Szenariopreis

B

Basis

Basis · 50%CGC

$1.69

Szenariopreis

B

Bärisch

Bärisch · 25%CGC

$1.41

Szenariopreis

Event-Zeitleiste

2026-09-28 (ET)

08:00:00

Canopy Growth Appoints Sebastian Blote as Country Manager for Germany

08:00:00

Canopy Growth Appoints Sebastian Blote as Country Manager for Germany

2026-09-22 (ET)

08:00:00

Canopy Growth Supplies Medical Cannabis Flowers to the UK

2026-09-08 (ET)

08:00:00

Canopy Growth Expands Medical Cannabis Portfolio in Australia

2026-08-07 (ET)

07:30:00

Company Reports Q1 Revenue of C$100.4M

News

CGC FAQ – beantwortet von Alphio AI

Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany. It operates in the Healthcare sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Canopy Growth Corp is not a good buy right now due to its current price of 0.713, a very low RSI of 17.94 indicating oversold conditions, and a troubling forward P/E of 20.37, which suggests high expectations despite ongoing losses.

Community

Mehr ↗
0xSkewfalcon27.9.2026

As mid-term elections approach and marijuana legalization comes up for debate again, $CGC is a chart worth watching. A large triangle pattern is close to a breakout. If it can reclaim its 50 DMA, there could be upside ahead 📈🌿 $1+ looks fairly likely again in the near future.

Mehr anzeigen
Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln